Skip to main content

ITI logo h color2x 1

 

Immunomic Therapeutics negotiated an exclusive license to Annias Immunotherapeutics’ platform covering technology for targeting cytomegalovirus (CMV) antigens in cancer. The CMV immunotherapy platform was developed by John H. Sampson, M.D., Ph.D., and Duane A. Mitchell, M.D., Ph.D., at Duke University and licensed to Annias. Immunomic will combine the CMV platform with its own nucleic acid-based immunotherapy LAMP-Vax™ technology as a potential treatment for cancers that express CMV, including glioblastoma multiforme (GBM). Financial details of the licensing agreement were not disclosed

{iframe}http://www.genengnews.com/gen-news-highlights/immunomic-licenses-cmv-targeting-tech-from-annias-for-lamp-vax-cancer-vaccines/81254348?utm_medium=newsletter&utm_source=GEN+Daily+News+Highlights&utm_content=01&utm_campaign=GEN+Daily+News+Highlights_20170515{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.